Search

Author/Creator Raab, M.-S.

1. P926: DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DANTE TRIAL. (23rd June 2022)

Authors:
Leypoldt, L.; Gavriatopoulou, M.; Besemer, B.; Salwender, H.; Raab, M.-S.; Nogai, A.; Khandanpour, C.; Runde, V.; Zago, M.; Martus, P.; Goldschmidt, H.; Bokemeyer, C.; Dimopoulos, M.; Weisel, K.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
816
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3. (23rd June 2022)

Authors:
Lesokhin, A. M.; Arnulf, B.; Niesvizky, R.; Mohty, M.; Bahlis, N. J.; Tomasson, M. H.; Rodrίguez-Otero, P.; Quach, H.; Raje, N. S.; Iida, S.; Raab, M.-S.; Czibere, A.; Sullivan, S.; Leip, E.; Viqueira, A.; Leleu, X.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
839
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. P959: CILTACABTAGENE AUTOLEUCEL IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY: CARTITUDE-2 BIOLOGICAL CORRELATIVE ANALYSES AND UPDATED CLINICAL DATA. (23rd June 2022)

Authors:
Hillengass, J.; Cohen, A. D.; Delforge, M.; Einsele, H.; Goldschmidt, H.; Weisel, K.; Raab, M.-S.; Scheid, C.; Schecter, J. M.; De Braganca, K. C.; Varsos, H.; Yeh, T.-M.; Mistry, P.; Roccia, T.; Corsale, C.; Akram, M.; Pacaud, L.; Nesheiwat, T.; Agha, M.; Cohen, Y. C.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
849
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search